Small-Cap Stock from Pharma & Specialty Chemicals Sector Jumps 10 Per Cent as Board is Likely to Announce Stock Split Next Week
The stock is up by 34 per cent from its 52-week low of Rs 333 per share.
Today, shares of IOL Chemicals & Pharmaceuticals Ltd jumped 10 per cent to an intraday high of Rs 446.55 per share from its previous closing of Rs 405.95 per share. The stock’s 52-week high is Rs 537.05 per share and its 52-week low is Rs 333 per share. The shares of the company saw a spurt in volume by more than 7.53 times on BSE.
The Board of Directors of IOL Chemicals & Pharmaceuticals Ltd will be holding a meeting on Friday, December 27, 2024 inter-alia to consider and approve the alteration in the share capital of the Company by sub-division/stock split of existing equity shares having face value of Rs 10 each, fully paid up, as may be determined by the Board of Directors.
IOL Chemicals & Pharmaceuticals Ltd is a prominent player in the pharmaceutical and specialty chemicals industries. Renowned for its significant global market share, particularly in Ibuprofen production, the company caters to both domestic and international markets. It boasts a diverse product portfolio, including key APIs like Ibuprofen, Clopidogrel, Losartan Potassium, and Paracetamol. The company's strong focus on research and development, coupled with its state-of-the-art manufacturing facilities, enables it to deliver high-quality products to its customers.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
Talking about the financials, this BSE small-cap company has a market cap of Rs 2,593 crore. The company reported positive numbers in its Quarterly Results (Q2FY25) and annual results (FY24). The company reported net sales of Rs 526 crore and a net profit of Rs 19 crore in Q2FY25 while in its FY24 results, the company reported net sales of Rs 2,133 crore and a net profit of Rs 135 crore
The stock is up by 34 per cent from its 52-week low of Rs 333 per share. Investors should keep an eye on this pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.